Glioblastoma Therapeutics Network (GTN) (U19 Clinical Trial Required)

Updated Oct 20, 2026

Cooperative agreement from the National Institutes of Health, open to small businesses. Closes Jan 11, 2027, 83 days left.

Opportunity number	RFA-CA-27-005
Agency	National Institutes of Health
Funding type	Cooperative agreement
Field	Health
Award ceiling	$700,000
Expected number of awards	4
Total program funding	$4.4 million
Cost sharing or matching	Not required
Assistance listing	93.394, 93.395
Posted	Aug 31, 2026
Closes	Jan 11, 2027 (83 days left)
Add the deadline to	Google Calendar

Who can apply

State governments
County governments
City or township governments
Special district governments
Independent school districts
Public and state controlled institutions of higher education
Native American tribal governments (federally recognized)
Public housing authorities and Indian housing authorities
Native American tribal organizations (other than federally recognized tribal governments)
Nonprofits with 501(c)(3) status, other than institutions of higher education
Nonprofits without 501(c)(3) status, other than institutions of higher education
Private institutions of higher education
For-profit organizations other than small businesses
Small businesses
Others (see the eligibility notes)

Refer to Section III. Eligibility Information in the NOFO for additional information on eligibility.Foreign Organizations/International Collaborations:Non-domestic (non-U.S.) Entities (Foreign Organization) are not eligible to apply.Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.Foreign components, as defined in the NIH Grants Policy Statement, are not allowed.

Description

Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) solicits applications for research on novel therapies for adult glioblastoma (GBM). The goal is to improve the treatment of adult GBM by developing novel effective agents that can cross the blood brain barrier (BBB) and testing them clinically. Successful early-stage trials of new drugs from this NOFO would transition seamlessly to later stage trials using well-established NCI clinical trial mechanisms.To implement this concept, a highly collaborative GBM Therapeutics Network (GTN) of cross-cutting teams will be established, each team capable of driving therapeutic agent(s) from pre-clinical development, through investigational new drugs (IND) studies, into pilot clinical studies in humans.

Appropriate therapeutic agents include: (1) novel agents or (2) agents or combinations approved for other indications and repurposed for treatment of GBM following appropriate preclinical studies. The scope of the NOFO, from late pre-clinical through early (Phase 0/1) clinical studies, uniquely spans a gap in the GBM drug development process.

Full announcement and how to apply on Grants.gov

Health grants right now

There are 350 open federal grants in health that small businesses may apply for; 33 close within 30 days. The median award ceiling is $500,000; this grant offers up to $700,000. The agencies offering the most are National Institutes of Health, Centers for Disease Control and Prevention - ERA and Centers for Disease Control - NCBDDD. Grants in this field stay open a median of 1031 days; this one is open for 133 days.

Who has won this program before

Sloan-Kettering Institute For Cancer Research $264.0 million · from Jan 20, 1997
University Of Pittsburgh - Of The Commonwealth System Of Higher Education $128.8 million · from Jul 12, 2016
Duke University $119.4 million · from Jan 1, 1997
American College Of Radiology $115.5 million · from May 26, 2014
University Of Pittsburgh - Of The Commonwealth System Of Higher Education $115.3 million · from Sep 10, 1997

The largest grants and cooperative agreements under assistance listing 93.394, 93.395 with funding activity since Oct 1, 2025, from USAspending.gov. Amounts are each award's total.